This clinical trial is focused on studying sickle cell disease, a genetic condition that affects the red blood cells, causing them to become misshapen and leading to various health complications. The study will evaluate the effectiveness and safety of a treatment called etavopivat, also known by its code name FT-4202. Participants in the study will receive either etavopivat or a placebo, which is a substance with no active medication.

The purpose of the study is to determine if etavopivat is more effective than a placebo in treating adolescents and adults with sickle cell disease. Participants will take part in a series of assessments over the course of the study, which will last for a period of time. These assessments will help researchers understand how well the treatment works and its safety profile. The study will involve regular check-ups and monitoring to track any changes in the participants’ health and symptoms.

Throughout the study, researchers will pay close attention to the number of painful episodes known as vaso-occlusive crises, which are common in sickle cell disease. They will also monitor changes in hemoglobin levels, which is a protein in red blood cells that carries oxygen, and other health indicators. The goal is to see if etavopivat can reduce these painful episodes and improve overall health outcomes for those living with sickle cell disease.